Statins do not decrease small, dense low-density lipoprotein

Texas Heart Institute Journal

Volumn 37, Issue 4, 2010, Pages 421-428

  Choi, Cheol Ung ^a   Seo, Hong Seog ^a   Lee, Eun Mi ^b   Shin, Seung Yong ^a   Choi, Un Jung ^a   Na, Jin Oh ^a   Lim, Hong Euy ^a   Kim, Jin Won ^a   Kim, Eung Ju ^a   Rha, Seung Woon ^a   Park, Chang Gyu ^a   Oh, Dong Joo ^a  

^a Korea University College of Medicine   (South Korea)

^b Wonkwang University   (South Korea)

Author keywords

Antilipemic agents therapeutic use; Arteriosclerosis blood; Biological markers blood; Cholesterol, LDL analysis blood classification drug effects; Coronary artery disease prevention control therapy; Hyperlipidemias prevention control; LDL blood chemistry; Lipids; Lipoproteins; Particle size

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DENSITY GRADIENT CENTRIFUGATION; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; REPRODUCIBILITY;

AGED; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CENTRIFUGATION, DENSITY GRADIENT; CHOLESTEROL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PARTICLE SIZE; REPUBLIC OF KOREA; TREATMENT OUTCOME;

EID: 77957372327     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285(19): 2486-2497.
2. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, Shepherd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994;106(2):241-253.
3. Campos H, Moye LA, Glasser SP, Stampfer MJ, Sacks FM. Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA 2001;286(12):1468-1474.
4. Sacks FM, Campos H. Clinical review 163: Cardiovascular endocrinology: low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab 2003;88 (10):4525-4532.
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383-1389.
6. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335(14):1001-1009.
7. Mudd JO, Borlaug BA, Johnston PV, Kral BG, Rouf R, Blumenthal RS, Kwiterovich PO Jr. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J Am Coll Cardiol 2007;50(18):1735-1741.
8. Berneis K, Rizzo M. LDL size: does it matter? Swiss Med Wkly 2004;134(49-50):720-774.
9. Franceschini G, Cassinotti M, Vecchio G, Gianfranceschi G, Pazzucconi F, Murakami T, et al. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. Arterioscler Thromb 1994;14(10):1569-1575.
10. Gaw A, Packard CJ, Murray EF, Lindsay GM, Griffin BA, Caslake MJ, et al. Effects of simvastatin on apoB metabolism and LDL subfraction distribution. Arterioscler Thromb 1993;13(2):170-189.
11. Superko HR, Krauss RM, DiRicco C. Effect of f luvastatin on low-density lipoprotein peak particle diameter. Am J Cardiol 1997;80(1):78-81.
12. Anuurad E, Shiwaku K, Enkhmaa B, Nogi A, Kitajima K, Yamasaki M, Yamane Y. Ethnic differences in the formation of small LDL particles in Asians: a comparison of Koreans, Japanese and Mongolians. Eur J Clin Invest 2004;34(11):738-746.
13. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97(18):1837-1847.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28(7):412-419.
15. Griffin BA, Caslake MJ, Yip B, Tait GW, Packard CJ, Shepherd J. Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 1990;83(1):59-67.
16. Hulthe J, Wiklund O, Olsson G, Fagerberg B, Bokemark L, Nivall S, Wikstrand J. Computerized measurement of LDL particle size in human serum. Reproducibility studies and evaluation of LDL particle size in relation to metabolic variables and the occurrence of atherosclerosis. Scand J Clin Lab Invest 1999;59(8):649-661.
17. Elovson J, Chatterton JE, Bell GT, Schumaker VN, Reuben MA, Puppione DL, et al. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res 1988;29(11):1461-1473.
18. St-Pierre AC, Bergeron J, Pirro M, Cantin B, Dagenais GR, Despres JP, Lamarche B. Effect of plasma C-reactive protein levels in modulating the risk of coronary heart disease associated with small, dense, low-density lipoproteins in men (The Quebec Cardiovascular Study). Am J Cardiol 2003;91(5):555-558.
19. Maki KC, Davidson MH, Marx P, Cyrowski MS, Maki A. Association between elevated plasma fibrinogen and the small, dense low-density lipoprotein phenotype among postmenopausal women. Am J Cardiol 2000;85(4):451-456.
20. Slyper AH, Zvereva S, Schectman G, Hoffmann RG, Mueller RA, Walker JA. Insulin resistance is not a major determinant of low-density lipoprotein particle size. Metabolism 1997;46 (11):1275-1280.
21. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement [published errata appear in Circulation 2005;112(17):e297,e298]. Circulation 2005;112(17):2735-2752.
22. Vekic J, Topic A, Zeljkovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V. LDL and HDL subclasses and their relationship with Framingham risk score in middle-aged Serbian population. Clin Biochem 2007;40(5-6):310-316.
23. Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res 1991;32(11):1741-1753.
24. Campos H, Blijlevens E, McNamara JR, Ordovas JM, Posner BM, Wilson PW, et al. LDL particle size distribution. Results from the Framingham Offspring Study. Arterioscler Thromb 1992;12(12):1410-1419.
25. Hulthe J, Bokemark L, Wikstrand J, Fagerberg B. The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study. Arterioscler Thromb Vasc Biol 2000;20(9):2140-2147.
26. Packard C, Caslake M, Shepherd J. The role of small, dense low density lipoprotein (LDL): a new look. Int J Cardiol 2000; 74 Suppl 1:S17-22.
27. Caslake MJ, Packard CJ. Phenotypes, genotypes and response to statin therapy. Curr Opin Lipidol 2004;15(4):387-392.